baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Knock-Out ABBV/ DE000VD4FH56 /

2024-05-31 9:36:51 PM	Chg.-	Bid9:37:21 AM	Ask9:37:21 AM	Underlying	Strike price	Expiration date	Option type
2.18EUR	-	2.38 Bid Size: 6,000	- Ask Size: -	AbbVie Inc	135.64 USD	2078-12-31	Call

GlobeNewswire 06-01 CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation ...

GlobeNewswire 05-30 OSE Immunotherapeutics Provides Business and Corporate Update

GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 05-28 Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Imp...

GlobeNewswire 05-28 CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...

GlobeNewswire 05-28 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

GlobeNewswire 05-25 CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...

GlobeNewswire 05-24 Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...

GlobeNewswire 05-23 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...

GlobeNewswire 05-22 Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...

GlobeNewswire 05-22 Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...

GlobeNewswire 05-22 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire 05-22 Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...

GlobeNewswire 05-22 Anavex Life Sciences Announces Expansion of Leadership Team

GlobeNewswire 05-22 OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...

GlobeNewswire 05-21 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

GlobeNewswire 05-21 BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...

GlobeNewswire 05-21 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

GlobeNewswire 05-17 INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerev...

GlobeNewswire 05-16 CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire 05-16 Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

GlobeNewswire 05-14 CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough...

GlobeNewswire 05-14 Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

GlobeNewswire 05-14 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...

GlobeNewswire 05-14 In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit

BVT Knock-Out ABBV/ DE000VD4FH56 /

If you wish to receive reply to your feedback, please provide your email address.